Genicular Nerve Phenol Neurolysis Versus Radiofrequency Ablation for Pain Relief in Grade 4 Knee Osteoarthritis

Status

Not yet recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06864390

Enrollment

114

Registered

2025-03-07

Start date

2025-04-30

Completion date

2025-11-30

Last updated

2025-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Joint Pain

Keywords

phenol neurolysis, radiofrequency, Knee osteoarthritis

Brief summary

The goal of this clinical trial is to compare the efficiency and efficacy of genicular nerves blockade by chemical phenol neurolysis versus radiofrequency ablation in managing pain in patients suffering from grade IV KOA in term of NRS pain score. The participants will be evaluated by numeric rating scale and oxford knee score for assessment of pain relief up to 16 weeks.

Interventions

PROCEDUREgenicular nerve neurolysis

The superior medial genicular nerve (SMGN), superior lateral genicular nerve (SLGN), and inferior medial genicular nerve (IMGN) will be blocked either by phenol neurolysis or radiofrequency ablation

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Grade 4 knee osteoarthritis according to Kellgren-Lawrence radiological classification. * Failure to manage pain with conservative methods.

Exclusion criteria

* Prior knee replacement * Patients with cardiac pacemakers or implantable cardiac defibrillators. * Septic knee or systemic sepsis. * Allergy to any of the drugs used in the study. * Coagulopathy or patients on anticoagulants. * Patients with psychiatric illness.

Design outcomes

Primary

Measure	Time frame	Description
Numeric rating scale	baseline, 2, 4, 8,12 and 16 weeks after the procedure	By an independent physician pain will be recorded using numeric rating scale which is a screening tool used to assess pain severity using a 0 - 10 scale with zero meaning no pain and 10 meaning the worst pain ever.

Secondary

Measure	Time frame	Description
oxford knee score	baseline, 4, 8, 12, 16 weeks after the procedure	This score is used to assess both function and pain of the knee on a scale ranging from 0 (worst pain and function) and 48 (best function and no pain) this score will be recorded by an independent physician

Contacts

Primary Contactahmed boeith, MD

ahmedabdelrahamn2008@med.asu.edu.eg02001003074795

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026